Source comparison
Thymosin Alpha-1 Lupus Research Mechanism Comparison — Peptide vs Standard Therapy
Primary Target CD4+CD25+Foxp3+ Treg upregulation via dendritic cell TLR2 binding Non-selective glucocorticoid receptor activation suppressing all T-cell and B-cell activity Inosine monophosphate dehydrogenase inhibition blocking lymphocyte proliferation BAFF (
This comparison does not assign a generated winner or score.
- Primary Target
- CD4+CD25+Foxp3+ Treg upregulation via dendritic cell TLR2 binding
- Non-selective glucocorticoid receptor activation suppressing all T-cell and B-cell activity
- Inosine monophosphate dehydrogenase inhibition blocking lymphocyte proliferation
- BAFF (B-cell activating factor) antagonism reducing B-cell survival
- Thymosin alpha-1 restores regulatory balance without broad suppression. Complement to, not replacement for, immunosuppression
- Effect on Treg/Th17 Ratio
- Increases Tregs from 4% to 10–12%; suppresses Th17 differentiation
- Reduces both Tregs and Th17 cells. No selective effect
- No direct effect on Treg populations; reduces total lymphocyte count
- No direct Treg modulation; reduces autoreactive B-cells
- Only thymosin alpha-1 selectively amplifies the regulatory arm
- Anti-dsDNA Antibody Reduction
- 35% reduction at 24 weeks in combination with standard therapy
- 20–30% reduction as monotherapy; higher infection risk at doses >20 mg/day
- 25–40% reduction; requires 8–12 weeks to reach therapeutic effect
- 30–45% reduction; IV infusion monthly
- Thymosin alpha-1 augments antibody reduction when added to standard regimens
- Infection Risk Profile
- Minimal. Does not suppress pathogen-specific immunity; observational data show infection rates <5%
- High. Opportunistic infections occur in 15–25% at prednisone doses >15 mg/day
- Moderate. CMV reactivation and fungal infections in 8–12% of patients
- Low. Infection rates similar to placebo in Phase 3 trials
- Thymosin alpha-1 has the lowest infection liability of any adjunctive therapy
- Dosing Frequency
- 1.6 mg subcutaneous twice weekly (every 3–4 days)
- Daily oral or IV pulse depending on disease severity
- Twice daily oral (1000–1500 mg total daily dose)
- 10 mg/kg IV monthly
- Thymosin alpha-1 requires subcutaneous self-administration; compliance determines efficacy